Physician
Urology
Dr. Michael K. Brawer, MD
|
|
Give Review
Michael Brawer works in the field of Urology. He studied medicine at David Geffen School of Medicine at UCLA. David Geffen School of Medicine at UCLA is a one of the best medicals schools. David Geffen School of Medicine at UCLA is ranked 13/7 in Research/PrimaryCare. Michael K. Brawer, MD has written publications. He has 97 publications published with PubMed. The lastest paper is: 'Differences in prostate size between patients from University and Veterans Affairs Medical Center populations.'
Publications
- Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer.
- Cell cycle progression score and treatment decisions in prostate cancer: Results from an ongoing registry.
- Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer.
- Best of the AUA Annual Meeting: Highlights From the 2011 American Urological Association Meeting, May 14-19, 2011, Washington, DC.
- Best of the AUA Annual Meeting: Highlights From the 2010 American Urological Association Meeting, May 29-June 3, 2010, San Francisco, CA.
- The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled ...
- Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL.
- Best of the 2008 AUA Annual Meeting: Highlights from the 2008 Annual Meeting of the American Urological Association, May 17-22, 2008, Orlando, FL.
- New treatments for castration-resistant prostate cancer: highlights from the 44th annual meeting of the american society of clinical oncology, may 30-june 3, 2008, chi...
- Recent Progress in the Treatment of Advanced Prostate Cancer With Intermittent Dose-Intense Calcitriol (DN-101).
- Best of the 2007 AUA Annual Meeting: Highlights from the 2007 Annual Meeting of the American Urological Association, May 19-24, 2007, Anaheim, CA.
- Hormonal therapy for prostate cancer.
- Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program.
- Prostatic intraepithelial neoplasia: an overview.
- Lonidamine: basic science and rationale for treatment of prostatic proliferative disorders.
- A Multicenter Study on the Efficacy and Safety of Interstitial Laser Coagulation Versus alpha-Blockade in Subjects With Symptomatic Benign Prostatic Hyperplasia: Preli...
- Challenges with luteinizing hormone-releasing hormone agonists: flare and surge.
- Androgen deprivation therapy: a cornerstone in the treatment of advanced prostate cancer.
- Testosterone replacement in men with andropause: an overview.
- Testosterone replacement therapy for a man with prostate cancer.
- Management of localized prostate cancer.
- Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer.
- A neurocomputational model for prostate carcinoma detection.
- Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
- Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial.
- Early diagnosis and staging of prostate cancer.
- Assays for complexed prostate-specific antigen and other advances in the diagnosis of prostate cancer.
- Androgen supplementation and prostate cancer risk: strategies for pretherapy assessment and monitoring.
- Attitudes and use of complementary medicine in men with prostate cancer.
- Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis.
- Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen?
- Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.
- Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer.
- Clinical usefulness of assays for complexed prostate-specific antigen.
- Selecting treatment for high-risk, localized prostate cancer: the case for radiation therapy.
- Urology Update from Jackson Hole: Highlights from the 3rd Annual Jackson Hole Summer Urologic Conference July 28-August 3, 2001, Jackson Hole, WY.
- Chemoprevention strategies in the prostate: an overview.
- Radiation therapy failure in prostate cancer patients: risk factors and methods of detection.
- Exploration of new pathologic factors in terms of potential for prognostic significance and future applications.
- The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
- Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer: the argument for.
- Vasectomy and prostate cancer: a case-control study in a health maintenance organization.
- Prostatic intraepithelial neoplasia: significance and management.
- Chemoprevention for prostatic intraepithelial neoplasia.
- Role of transrectal ultrasound and prostate biopsy.
- Age-specific prostate-specific antigen: a reassessment.
- Multicenter comparison of the diagnostic performance of free prostate-specific antigen.
- Enhancing the specificity of prostate-specific antigen (PSA): an overview of PSA density, velocity and age-specific reference ranges.
- Comparison of three commercial PSA assays: results of restandardization of the Ciba Corning method.
- Biological variation of prostate specific antigen levels in serum: an evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients.
- Histologic differences in benign prostate hyperplasia between Chinese and American men.
- The Prostate Cancer Intervention Versus Observation Trial (PIVOT).
- Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994.
- Development of a decision-making tool to predict risk of prostate cancer: the Cancer of the Prostate Risk Index (CAPRI) test.
- Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer.
- Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical...
- Transition zone prostate specific antigen density: lack of use in prediction of prostatic carcinoma.
- Comparison of 3 investigational assays for the free form of prostate specific antigen.
- Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma.
- Measurement of complexed PSA improves specificity for early detection of prostate cancer.
- Predicting outcomes of therapy for prostate carcinoma patients.
- The effect of prostate volume on the yield of needle biopsy.
- Prostate cancer in relation to the use of electric blanket or heated water bed.
- Differences in prostate size between patients from University and Veterans Affairs Medical Center populations.
- What will replace TURP?
- Modeling the impact of prostate cancer early diagnosis on managed care plans.
- An actuarial model approach to assessing the impact of serial testing for prostate cancer using the Tandem PSA assay.
- Effect of age, educational status, ethnicity and geographic location on prostate symptom scores.
- What''s in a teaspoon? Underdosing with acetaminophen in family practice.
- New relationships between prostatic intraepithelial neoplasia and prostatic carcinoma.
- Osteogenic sarcoma after retinoblastoma radiotherapy.
- Best of the 2013 AUA Annual Meeting: Highlights From the 2013 American Urological Association Meeting, May 4-8, 2013, San Diego, CA.
- Transrectal ultrasonography of the prostate.
- Clinical Evidence: Non-metastatic prostate cancer.
- Prostate cancer: epidemiology and screening.
- Quantitative morphometric analysis of the microcirculation in prostate carcinoma.
- Prostate cancer: serum and tissue markers.
- Prostate cancer: risk assessment and diagnostic approaches.
- Androgen deprivation and other treatments for advanced prostate cancer.
- The evolution of hormonal therapy for prostatic carcinoma.
- Modern brachytherapy for localized prostate cancers: the northwest hospital (Seattle) experience.
- Letter from the editors of reviews in urology.
- Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer.
- Readership survey: reviews in urology.
- New urologic strategies explored at jackson hole: highlights from the 20th annual jackson hole urologic conference january 22-28, 2000, jackson hole, wyo.
- Stones, BPH, Renal and Prostate Disease Discussed at Jackson Hole: Highlights from the 19th Annual Jackson Hole Urologic Conference January 23-30, Jackson Hole, Wyo.
- Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA.
- Effect of finasteride and/or terazosin on serum PSA: results of VA Cooperative Study #359.
- Complexed PSA: the newest advance in PSA testing.
- Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clin...
- Vasectomy and risk of prostate cancer.
- Evaluation of prostate cancer patients receiving multiple staging tests, including ProstaScint scintiscans.
- Prostate-specific antigen.
- Prostate-specific antigen and other serum markers: current concepts from the World Health Organization Second International Consultation on Prostate Cancer.
- Report on Prostate Cancer Tumor Marker Workshop 1999.
- Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial.
Schools
University of California At Los Angeles
Stanford University
Doctors Specialties
- Urology
Accepted Insurances
Education
-
Stanford University -
David Geffen School of Medicine at UCLA
Helpful Reviews
Similar Doctors
|
|
Dr. Mark W. Burns III, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John S. Mullen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel W. Lin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jonathan L. Wright, MD |
|
|
Dr. Hunter A. McKay, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maahum A. Haider, MD |
|
|
Dr. Marc A. Lowe, MD |
|
|
Dr. Laura S. Leddy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Justin S. Ahn, MD |
|
|
Dr. Alvaro Lucioni, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew N. Mossanen, MD |